Spark prices Luxturna, eyes new payment models

Spark Therapeutics Inc. (NASDAQ:ONCE) priced Luxturna voretigene neparvovec-rzyl at $425,000 per eye and announced an outcomes-based pricing arrangement for the gene therapy. The company is also setting the stage with the Centers for Medicare & Medicaid Services (CMS) to potentially test a payment-over-time pricing model with commercial and government payers.

FDA approved Luxturna on Dec. 19 to treat biallelic retinal pigment epithelium-specific protein 65kDa (RPE65) mutation-associated retinal dystrophy. The majority of

Read the full 705 word article

User Sign In